Evidence map›Paper›PMID 29589874›Full record

ArticleStem cells translational medicine2018

Genome Editing in Neuroepithelial Stem Cells to Generate Human Neurons with High Adenosine-Releasing Capacity.

Daniel Poppe, Jonas Doerr, Marion Schneider, Ruven Wilkens, Julius A Steinbeck, Julia Ladewig, Allison Tam, David E Paschon, Philip D Gregory, Andreas Reik and 3 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Emerging Role of Purine Metabolizing Enzymes in Brain Function and Tumors.International journal of molecular sciences · 2018
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Daniel PoppeInstitute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, Bonn, Germany.
Jonas DoerrInstitute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, Bonn, Germany.
Marion SchneiderPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Ruven WilkensInstitute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, Bonn, Germany.
Julius A SteinbeckInstitute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, Bonn, Germany.
Julia LadewigInstitute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, Bonn, Germany.
Allison TamSangamo Therapeutics, Richmond, California, USA.
David E PaschonSangamo Therapeutics, Richmond, California, USA.
Philip D GregorySangamo Therapeutics, Richmond, California, USA.
Andreas ReikSangamo Therapeutics, Richmond, California, USA.
Christa E MüllerPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.ORCID 0000-0002-0013-6624
Philipp KochInstitute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, Bonn, Germany.ORCID 0000-0003-3713-8786
Oliver BrüstleInstitute of Reconstructive Neurobiology, University of Bonn and Hertie Foundation, Bonn, Germany.
University of Bonn · DESangamo BioSciences (United States) · USGerman Cancer Research Center · DEHertie Foundation · DELife & Brain (Germany) · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a powerful regulator of cellular homeostasis and metabolism, adenosine is involved in diverse neurological processes including pain, cognition, and memory. Altered adenosine homeostasis has also been associated with several diseases such as depression, schizophrenia, or epilepsy. Based on its protective properties, adenosine has been considered as a potential therapeutic agent for various brain disorders. Since systemic application of adenosine is hampered by serious side effects such as vasodilatation and cardiac suppression, recent studies aim at improving local delivery by depots, pumps, or cell-based applications. Here, we report on the characterization of adenosine-releasing human embryonic stem cell-derived neuroepithelial stem cells (long-term self-renewing neuroepithelial stem [lt-NES] cells) generated by zinc finger nuclease (ZFN)-mediated knockout of the adenosine kinase (ADK) gene. ADK-deficient lt-NES cells and their differentiated neuronal and astroglial progeny exhibit substantially elevated release of adenosine compared to control cells. Importantly, extensive adenosine release could be triggered by excitation of differentiated neuronal cultures, suggesting a potential activity-dependent regulation of adenosine supply. Thus, ZFN-modified neural stem cells might serve as a useful vehicle for the activity-dependent local therapeutic delivery of adenosine into the central nervous system. Stem Cells Translational Medicine 2018;7:477-486.

Indexed as

AdenosineAdenosine KinaseAnimalsCell LineChromatography, High Pressure LiquidGene EditingHuman Embryonic Stem CellsHumansKaryotypingMass SpectrometryMiceMice, Inbred C57BLMice, KnockoutNeural Stem CellsNeuronsPolymorphism, Single NucleotideAdenosineAdenosine KinaseZinc Finger NucleasesAdenosine kinaseAdenosine secretionGene-editingHuman neuronsNeuroepithelial stem cells

Identifiers

PMID29589874
PMCPMC5980162
OpenAlexW2794830789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.